Browsing: Perspectives

For years, the industry underpriced rare disease, undervalued underserved patients, and treated Chinese biotech as a discount aisle. This week,…

This week gave us three distinct stories — a landmark FDA approval, a $3.8 billion M&A announcement, and a quietly…